Virocyt And I&L Biosystems Launch Virus Counter® 3100 At The World Vaccine Congress In Brussels

BOULDER, CO--(Marketwired - October 02, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that, in partnership with I&L Biosystems GmbH, it is formally launching the Virus Counter® 3100 in Europe at the World Vaccine Congress to be held October 13-15 in Brussels, Belgium.

“The Virus Counter 3100 is the marquee analytical tool for quickly quantifying viruses, and we see exceptional opportunity in the European virology community,” said Robert Kline, ViroCyt’s President and CEO. “Our technology has already been embraced by leading vaccine companies, regulatory agencies, research institutes and universities, and we see the improvements embodied by the 3100 system accelerating this trend.”

According to Alexander Beljaars, Managing Director of I&L, “As the European distributor of the Virus Counter, we are delighted with the enhanced capabilities of the 3100, including the addition of an optional autosampler for walk away processing of up to 96-samples and compliant software for GMP environments. These and other added elements will facilitate the adoption of the Virus Counter deeper into manufacturing settings where real-time assessment of viral preparations is essential.”

“That ViroCyt and I&L chose to debut their breakthrough technology to the European market at the World Vaccine Congress speaks volumes. It’s our pleasure to help them get the word out, and that this year’s event is being held in the Benelux region where many of the world’s vaccines are developed and produced, will facilitate this,” stated Georgia McCollum, General Manager of Terrapinn’s Life Science Practice.

About ViroCyt, LLC
ViroCyt, LLC was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.